Logo

A Mosaic of Uncertainty

Apr 22, 2010

Targeted therapies are only as good as the tests that determine whether they are warranted, says this article in the New York Times. In it, Linda Griffith, the head of MIT's Center for Gynepathology Research, says that she has seen this both as a researcher and as a patient. Her Her2 test on a breast biopsy came back as a mosaic and whether or not she should take Herceptin was unclear. In addition, a Mayo clinic study a few years ago found that labs often disagreed on the test results, and that led to the adoption of Her2 testing guidelines, though there can still be incongruities about results. Genentech's Krysta Pellegrino tells the Times that "we're still trying to refine the testing."

Breaking News
The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.